E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Published on 12/23/2005 in the Prospect News Biotech Daily and Prospect News Convertibles Daily.

New Issue: Morgan Stanley prices $23 million 7.5% Sparqs exchangeable for Gilead Sciences

By Jennifer Chiou

New York, Dec. 23 - Morgan Stanley priced $23,000,002.50 of 7.5% Sparqs (Stock Participation Accreting Redemption Quarterly-pay Securities) due Jan. 15, 2007 that are mandatorily exchangeable for Gilead Sciences, Inc. stock, according to a 424B3 filing with the Securities and Exchange Commission.

Issuer:Morgan Stanley
Issue:Sparqs (Stock Participation Accreting Redemption Quarterly-pay Securities) senior medium-term notes, series F
Underlying stock:Gilead Sciences, Inc.
Amount:$23,000,002.50
Maturity:Jan. 15, 2007
Coupon:7.5%, payable quarterly
Price:Par of $13.85 (equal to one-quarter of closing price of Gilead Sciences stock on pricing date)
Exchange ratio:0.25 (mandatory, at maturity)
Call:July 15, 2006 onwards at price to give yield to call of 20%
Pricing date:Dec. 22
Settlement date:Dec. 30
Underwriter:Morgan Stanley
Listing:"GSY" on American Stock Exchange

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.